Document Detail


Resisting the urge to smoke and craving during a smoking quit attempt on varenicline: results from a pilot fMRI study.
MedLine Citation:
PMID:  23421569     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Varenicline has been shown to reduce cigarette craving during a quit attempt.
OBJECTIVES: Use BOLD fMRI to explore differences in smoking cue reactivity at baseline and after five weeks of varenicline smoking cessation treatment.
METHODS: Treatment-seeking nicotine-dependent adult smokers underwent BOLD fMRI scans with block presentation of visual smoking, neutral, and rest cues under two conditions: craving or resisting the urge to smoke at baseline and following 5 weeks of standard varenicline therapy. Data were analyzed using FMRI Expert Analysis Tool, version 5.98 of Functional Magnetic Imaging of the Brain Software Library focused on the smoking vs. neutral cue contrast at the individual and group level, Z>2.3 with cluster threshold p=0.05.
RESULTS: Twenty-one participants were scanned at baseline and 16 completed the study; 10 were abstinent at the 2(nd) session, confirmed with urinary cotinine. In the Crave Condition no significant differences were found between the abstinent and non-abstinent groups at either time point. During the baseline Resist Condition, the abstinent group compared to the non-abstinent group demonstrated activation in a distributed network involved in alertness, learning and memory. Additionally, within the abstinent group, increased activation of the superior frontal gyrus was found at baseline compared to week 5.
CONCLUSION: Successful smoking cessation with varenicline is associated with increased activation, prior to a quit attempt, in brain areas related to attentiveness and memory while resisting the urge to smoke Scientific Significance: Varenicline may exert effects by both reducing craving and enhancing resistance to smoking urges during cue-elicited craving.
Authors:
Karen J Hartwell; Todd Lematty; Aimee L McRae-Clark; Kevin M Gray; Mark S George; Kathleen T Brady
Related Documents :
2135709 - Scopolamine and physostigmine do not alter visual detection of change: relationships to...
23449939 - Active, passive and motor imagery paradigms: component analysis to assess neurovascular...
22924659 - Naturalistic measures of prospective memory in amnestic mild cognitive impairment.
1616609 - Scopolamine deficits in negative patterning discrimination: evidence for a role of the ...
23523269 - Functional brain connectivity and cognition: effects of adult age and task demands.
23246789 - Selling points: what cognitive abilities are tapped by casual video games?
2135709 - Scopolamine and physostigmine do not alter visual detection of change: relationships to...
18597749 - Disconnection in prosopagnosia and face processing.
12244209 - Neural basis of protracted developmental changes in visuo-spatial working memory.
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, N.I.H., Extramural    
Journal Detail:
Title:  The American journal of drug and alcohol abuse     Volume:  39     ISSN:  1097-9891     ISO Abbreviation:  Am J Drug Alcohol Abuse     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-20     Completed Date:  2014-01-17     Revised Date:  2014-04-11    
Medline Journal Info:
Nlm Unique ID:  7502510     Medline TA:  Am J Drug Alcohol Abuse     Country:  England    
Other Details:
Languages:  eng     Pagination:  92-8     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Arousal / physiology
Behavior, Addictive / drug therapy*,  physiopathology
Benzazepines / therapeutic use*
Cues
Female
Frontal Lobe / physiopathology
Functional Neuroimaging / psychology*
Humans
Learning / physiology
Male
Memory / physiology
Neural Pathways / physiopathology
Nicotinic Agonists / therapeutic use
Pilot Projects
Quinoxalines / therapeutic use*
Smoking / drug therapy,  physiopathology,  psychology*
Smoking Cessation / psychology*
Tobacco Use Disorder / drug therapy,  physiopathology,  psychology*
Grant Support
ID/Acronym/Agency:
5R21DA026085-02/DA/NIDA NIH HHS; K12 HD055885/HD/NICHD NIH HHS; K12HD055885/HD/NICHD NIH HHS; R21 DA026085/DA/NIDA NIH HHS; UL1 RR029882/RR/NCRR NIH HHS; UL1 RR029882/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/Benzazepines; 0/Nicotinic Agonists; 0/Quinoxalines; W6HS99O8ZO/varenicline

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Opioid-like effects of the neurokinin 1 antagonist aprepitant in patients maintained on and briefly ...
Next Document:  Perceptions of HIV Risk among Methamphetamine Users in China.